Lyndra has raised a total of $214.05m prior to the Series E round. Image credit: Shutterstock/ADragan.

Lyndra Therapeutics has raised $101m in a Series E financing round as the company looks to advance its long-lasting oral therapy pipeline.

The US biopharma company said the round, led by Sarissa Capital with participation from Sun Pharmaceutical Industries and Polaris Partners, will support the completion of a pivotal Phase III trial investigating its risperidone candidate LYN-005 in schizophrenia and schizoaffective disorder patients.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the financing, Sun Pharma will receive an exclusive license to manufacture and market three of Lyndra’s oral weekly candidates in six countries, including Brazil and India. The candidates wrapped in the deal include LYN-005, as well as the company’s formulations of dapagliflozin (LYN-045) for type 2 diabetes and antipsychotic medicine aripiprazole (LYN-006), according to a 21 December press release.

Lyndra develops its long-lasting oral therapies using its LYNX drug delivery platform spun out of MIT. According to the company, it creates medicines that last for a week or longer in oral dosage. Lyndra’s standard-sized capsules house drug-containing elements that maintain their shape in the gastrointestinal tract to enable correct dosage. These then disintegrate when the dosing period is complete. The platform is designed for steady drug release over a seven-day period, with the company eyeing up monthly regimen pills in the future.

Lyndra is nearing completion of a pivotal phase III trial investigating the pharmacokinetics and safety/tolerability profile of LYN-005. The LYN-005-C-301 study (NCT05779241) is slated to enrol 90 patients with schizophrenia or schizoaffective disorder. The first participant was dosed in May 2023.

See Also:

Lyndra Therapeutics’ President and CEO Jessica Ballinger said: “We appreciate the support our investors are providing as we complete our risperidone phase 3 trials and continue the development of our pipeline of oral weekly therapies through this round of financing

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lyndra has received funding from AbbVie, the Bill & Melinda Gates Foundation, and the National Institutes of Health. In July 2019, Gilead Sciences partnered with Lyndra to develop long-acting human immunodeficiency virus (HIV) drugs.

Prior to the Series E round, Lyndra has raised a total of $214.05m through venture financing, according to GlobalData’s Pharma Intelligence Centre.

GlobalData is the parent company of Pharmaceutical Technology.

In September 2023, a Lyndra spokesperson told various outlets the company was laying off 23% of its workforce to trim operations costs.